Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | MST1R | Q04912 | 1/20 | 0.37 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27513381 | 0.85 | FDFT1 (0.38) | ALOX5FDFT1CYP26A1 | |
| SCHEMBL25810696 | 0.84 | PTGS2 (0.47) | ALOX5 | |
| SCHEMBL1515610 | 0.80 | EPHX1 (0.47) | EPHX1ALOX5APPMETMST1R | |
| SCHEMBL25295103 | 0.79 | HPGD (0.41) | FDFT1CYP26A1KMT2A | |
| SCHEMBL1515561 | 0.79 | NNMT (0.56) | EPHX1MKNK1MKNK2MEN1KMT2A | |
| SCHEMBL30489970 | 0.79 | HPGD (0.41) | FDFT1CYP26A1KMT2A | |
| SCHEMBL27800860 | 0.78 | ALOX5 (0.36) | EPHX1ALOX5FDFT1MAPK1MEN1 | |
| SCHEMBL22509374 | 0.76 | EPHX1 (0.47) | EPHX1ALOX5APPMETMST1R | |
| SCHEMBL12614358 | 0.75 | ADRB2 (0.41) | FDFT1CYP26A1 | |
| SCHEMBL3875094 | 0.75 | EPHX1 (0.58) | EPHX1ALOX5APPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516056-B2 | Compounds for inhibition of janus kinase 1 | MANKIND PHARMA LTD. (IN) | 2026-01-06 | — | — | US | disclosed |
| CN-114174294-B | Novel compounds for inhibiting JANUS kinase 1 | 人类制药有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD. (IN) | 2022-07-28 | — | — | US | disclosed |
| EP-3976612-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD (IN) | 2022-04-06 | — | — | EP | disclosed |
| CN-114174294-A | Novel compounds for inhibiting JANUS kinase 1 | 人类制药有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021227906-A1 | PYRIDINE ACETAMIDE DERIVATIVE SERVING AS CDK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| WO-2020240586-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD. (IN) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020240586-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD. (IN) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | JAK1, JAK2, JAK3 | EPHX1 3205/4885ALOX5 2761/4885APP 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.